Company CorMedix Inc.

CRMD

US21900C3088

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
5.05 ^USD	-1.37%		-4.72%	+34.31%

May. 09	Transcript : CorMedix Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Number of employees: 83

Managers	Title	Age	Since
Joseph Todisco CEO	Chief Executive Officer	48	22-03-17
Mathew David DFI	Director of Finance/CFO	47	20-05-10
Tushar Mukherjee CTO	Chief Tech/Sci/R&D Officer	-	21-12-31
Beth Zelnick Kaufman LAW	General Counsel	-	Dec. 11
Erin Mistry PRN	Corporate Officer/Principal	43	19-12-31
Frank Raffaele PRN	Corporate Officer/Principal	-	22-05-11
Donna Ucci PRN	Corporate Officer/Principal	-	22-05-11
Elizabeth Masson-Hurlburt PRN	Corporate Officer/Principal	45	18-02-28

Members of the board	Title	Age	Since
Myron Kaplan CHM	Chairman	79	16-04-26
Steven Lefkowitz DFI	Director of Finance/CFO	68	11-08-14
Alan Dunton BRD	Director/Board Member	70	19-02-28
Janet Dillione BRD	Director/Board Member	65	15-08-05
Joseph Todisco CEO	Chief Executive Officer	48	22-03-17
Gregory Duncan BRD	Director/Board Member	59	20-11-01
Robert Stewart BRD	Director/Board Member	56	23-04-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	54,959,270	54,452,031 ( 99.08 %)	0	99.08 %
Stock B	0	181,622	0	0

Name	Equities	%	Valuation
BlackRock Advisors LLC 6.080 %	3,342,956	6.080 %	17 M $
NOMURA HOLDINGS, INC. 5.368 %	2,951,439	5.368 %	15 M $
Vanguard Fiduciary Trust Co. 5.326 %	2,928,186	5.326 %	15 M $
Elliott Investment Management LP 2.820 %	1,550,523	2.820 %	8 M $
Geode Capital Management LLC 2.152 %	1,183,172	2.152 %	6 M $
STATE STREET CORPORATION 2.019 %	1,109,858	2.019 %	6 M $
Northern Trust Investments, Inc.(Investment Management) 0.7667 %	421,549	0.7667 %	2 M $
Joseph Todisco 0.5927 %	325,857	0.5927 %	2 M $
Renaissance Technologies LLC 0.4341 %	238,659	0.4341 %	1 M $
Susquehanna Securities LLC 0.3744 %	205,862	0.3744 %	1 M $

CorMedix, Inc.

300 Connell Drive Suite 4200

07922, Berkeley Heights

+908 517 9500

http://www.cormedix.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.05 USD

Average target price

13 USD

Spread / Average Target

+157.43%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CORMEDIX INC.	+34.31%	278M
MERCK KGAA	+15.20%	78.65B
KYOWA KIRIN CO. LTD.	+9.32%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.16B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+54.31%	4.85B
YUHAN CORPORATION	+11.19%	4.19B
BETTA PHARMACEUTICALS CO., LTD.	-22.37%	2.32B
INDIVIOR PLC	+12.57%	2.29B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-30.09%	2.19B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+20.63%	2.19B

Specialty & Advanced Pharmaceuticals